Back to search

Pharmaron Biologics (Uk) Ltd

04543737

active
ltd
england wales
Companies House
Health Score
63 / 100

Some Concerns

25/30
Filing
0/30
Financial
38/40
Risk
  • No accounts filed in last 18 months (-5)
  • Loss before tax (-10)
  • Going concern doubt noted in accounts (-10)
  • 1 outstanding charge (-2)

Details

12 Estuary Banks, Speke, Liverpool, L24 8RB
Incorporated 24/09/2002

Previously known as

Allergan Biologics Limited · until 14/05/2021
Actavis Biologics Limited · until 07/01/2016
Eden Biodesign Limited · until 31/03/2014
Hallco 826 Limited · until 20/11/2002

Compliance

Last accounts

31/12/2025

full

Next accounts due

30/09/2027

On track

Confirmation statement

Last: 20/05/2026

Due 03/06/2027

On track

Industry

21100
Manufacture of basic pharmaceutical products

Officers

Mr Stephen Lewinton

secretary · Since 30/04/2021

Dr Boliang Lou

director · Since 30/04/2021

CEO

AMERICAN · UNITED STATES

Mr. Stephen Christopher Lewinton

director · Since 26/10/2021

SENIOR MANAGER

BRITISH · UNITED KINGDOM

Also on 4 other boards

Stephen Lewinton

secretary · Since 30/04/2021

Boliang Lou

director · Since 30/04/2021

American · United States

Stephen Christopher Lewinton

director · Since 26/10/2021

British · United Kingdom

Former

Halliwells Directors Limited

corporate nominee director · Resigned 12/11/2002

Halliwells Secretaries Limited

corporate nominee secretary · Resigned 12/11/2002

Neil Julian Rothwell

secretary · Resigned 01/06/2004

Anita Susan Bate

secretary · Resigned 28/01/2010

Fred Wilkinson

director · Resigned 25/04/2014

David Adam Buchen

director · Resigned 01/05/2015

Paul Mino Bisaro

director · Resigned 03/11/2015

Janice Elizabeth Stewart

director · Resigned 30/06/2017

Tom Nelligan

secretary · Resigned 13/10/2017

Judith Tomkins

secretary · Resigned 02/10/2020

Crawford David Brown

director · Resigned 30/04/2021

Patricia Maria Haran

secretary · Resigned 30/04/2021

Persons with Significant Control

Pharmaron Biologics (Uk) Holdings Limited

75–100% shares
75–100% votes
Appoint directors

Notified 30/04/2021

Former PSCs

Eden Biopharma Group Limited

Ceased 31/05/2018

Allergan Plc

Ceased 08/05/2020

Agn Sundry Llc

Ceased 01/04/2019

Abbvie Inc.

Ceased 30/04/2021

Pharmaron Beijing Co Ltd

Ceased 02/08/2021

Charges1 outstanding

Charge
outstanding

HSBC UK BANK PLC

Created 03/02/2023Registered 09/02/2023

Change History

officer appointed → LEWINTON, Stephen
2026-08-19
officer appointed → LEWINTON, Stephen Christopher, Mr.
2026-08-19
officer appointed → LOU, Boliang, Dr
2026-08-19
status → active
2026-08-19

Active

type → ltd
2026-08-19

Private Limited Company

address line1 → 12 Estuary Banks
2026-08-19

12 ESTUARY BANKS

post town → Liverpool
2026-08-19

LIVERPOOL

CompanyRankvs 307+ SIC 21100 peers
34

Financial strength34th percentile among SIC peers · 9/25
Employees99th percentile among SIC peers · 15/15
LiquidityNo balance sheet data · 0/20
Longevity15 years trading (max 15) · 15/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10Outstanding charges -10
Show leaderboard
How is this score calculated?
Financial strength9/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees15/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity0/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity15/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Outstanding charges: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to

Key FinancialsYear ending 31/12/2024

Net Worth

£2

Balance sheet strength

Cash

—

Cash in the bank

Profit Before Tax

-£311k

Bottom line earnings

Net Current Assets

—

Working capital

Current Assets

—

Current Liabilities

—

Cost of Sales

£18.5M

Admin Expenses

£11.0M

Profit After Tax

-£330k

187avg. employees

People Costs

Wages & salaries£11.2M
Prepared with CCH Software